UK Prospective Diabetes Study (UKPDS) Risk Engine
Simplified UKPDS-based cardiovascular risk factors guide in T2DM. Score used to prioritise treatment intensity.
Score interpretation
Score 0–2: Relatively lower modifiable risk burden
→ Continue current management; annual HbA1c, lipids, BP, and renal function checks
Score 3–5: Moderate cardiovascular risk burden
→ Intensify glycaemic control; optimise BP (<130/80); statin therapy; smoking cessation
Score ≥6: High cardiovascular risk
→ Urgent multi-factor intervention; SGLT2i/GLP-1 agonist if appropriate; cardiology referral if CVD present; target HbA1c <53 mmol/mol
Interpretation bands for the UKPDS Risk. Apply clinical judgement and local guidance.
References
- Turner RC, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316:823-828.
Related
Curated clinical cross-links plus same-class fallbacks.
- Atorvastatin (CKD Cardiovascular Risk) · Cardiovascular Risk in CKD
- Icosapent Ethyl (Omega-3 — Cardiovascular Risk Reduction) · Omega-3 Fatty Acid (Purified EPA — Eicosapentaenoic Acid Ethyl Ester)
- Simvastatin with ezetimibe · HMG-CoA reductase inhibitor + cholesterol absorption inhibitor
- Bempedoic acid with ezetimibe · ATP-citrate lyase inhibitor + cholesterol absorption inhibitor
- Tenecteplase · Cardiovascular Emergency
- Tirofiban · Cardiovascular Emergency
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.